Compare AMS & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMS | NCEL |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 11 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 10.3M |
| IPO Year | 1995 | N/A |
| Metric | AMS | NCEL |
|---|---|---|
| Price | $1.34 | $3.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 111.7K | 64.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,714,000.00 | N/A |
| Revenue This Year | $6.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $1.25 | $1.83 |
| 52 Week High | $3.11 | $5.12 |
| Indicator | AMS | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.89 | 54.73 |
| Support Level | $1.27 | $2.50 |
| Resistance Level | $2.22 | $4.07 |
| Average True Range (ATR) | 0.11 | 0.44 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 17.00 | 41.14 |
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.